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TO THE EDITOR: In their recent article, Horvat et al1 evaluated
the effects of immune-related adverse events (irAEs) in about 300
patients with metastatic melanoma treated with ipilimumab. In
recent years, accumulating data suggested that ipilimumab supports
the activation of the immune system, thus promoting antitumor
immunity.2,3 However, immune system activation may induce in
turn normal tissue injury (ie, irAEs), which occurs in about 60% to
80% of patients treated.1,2 The authors observed that both irAEs
(any severity) and the administration of systemic immunosup-
pressive therapies (ie, corticosteroids) did not inﬂuence survival
outcome.1 This information is useful in clinical practice for patients
affected by metastatic melanoma treated with ipilimumab, in whom
corticosteroid use is generally avoided.1
However, the following points of this paper deserve to be
addressed. There is growing evidence showing that an (excessive)
activation of the immune response, leading to immune-related tox-
icities, is associated with an improved response to immunotherapy.3,4
By this point of view, it would be interesting to assess the prognosis of
patients who experienced severe irAEs with corticosteroid rescue. In
addition, the authors should clarify if the patients with irAEs achieved
a response to ipilimumab before the start of corticosteroid rescue. In
the latter case we can hypothesize that, when an efﬁcient immune
reaction is activated by ipilimumab, administration of immunosup-
pressive therapies does not inﬂuence response to treatment. In fact,
although the efﬁcacy of systemic steroids in suppressing immune
response is well known, the kinetics of development (time and dose
relation) of such immunosuppressive effect are not completely clear.5,6
In this regard, knowledge of the schedule and the dose of cortico-
steroid that had been used would be useful information.
Improving knowledge of the relationship between systemic
immune activation and clinical responses to immune therapies
would be helpful from a clinical point of view. In fact, an effective
immunotherapy should be continued even if patients experience
irAEs, making rescue with corticosteroids not harmful for their
activity. Further attempts are needed to improve the care of
patients and their quality of life.
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